Therapeutic Goods Administration
June 2017Updated July 2017
Australian Public Assessment Report for Etanercept (rch)
Proprietary Product Name: Samsung Bioepis AU Pty Ltd[1]
Sponsor:ERA Consulting
About the Therapeutic Goods Administration (TGA)
- The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices.
- The TGA administers the Therapeutic Goods Act 1989(the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary.
- The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices.
- The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action.
- To report a problem with a medicine or medical device, please see the information on the TGA website <
About AusPARs
- An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
- AusPARs are prepared and published by the TGA.
- An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications.
- An AusPAR is a static document; it provides information that relates to a submission at a particular point in time.
- A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
Copyright
© Commonwealth of Australia 2016
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <>.
Final 21 June 2017 / Page 1 of 70
Therapeutic Goods Administration
Contents
List of common abbreviations
I. Introduction to product submission
Submission details
Product background
Regulatory status
Product Information
II. Quality findings
Drug substance (active ingredient) and Drug product
Biopharmaceutics
Quality summary and conclusions
III. Nonclinical findings
Introduction
Pharmacology
Pharmacokinetics
Toxicology
Nonclinical summary and conclusions
IV. Clinical findings
Introduction
Pharmacokinetics
Pharmacodynamics
Dosage selection for the pivotal studies
Efficacy
Safety
First round benefit-risk assessment
First round recommendation regarding authorisation
Second round clinical evaluation of clinical data submitted in response to questions
Second round benefit-risk assessment
V. Pharmacovigilance findings
Risk management plan
VI. Overall conclusion and risk/benefit assessment
Quality
Nonclinical
Clinical
Risk management plan
Risk-benefit analysis
Outcome
Attachment 1. Product Information
Attachment 2. Extract from the Clinical Evaluation Report
List of common abbreviations
Abbreviation / MeaningACR / American College of Rheumatology
ADA / Anti-Drug Antibody
AE / Adverse Event
ANOVA / Analysis of Variance
AS / Ankylosing Spondylitis
AUCinf / Area Under Concentration-Time curve from time zero to infinity
AUClast / AUC-Time curve from time zero to last detectable drug concentration
BASDAI / Bath Ankylosing Spondylitis Disease Activity Index
BMI / Body Mass Index
CI / Confidence interval
CL/F / Apparent Drug Clearance
Cmax / Maximum serum concentration
CRP / C-Reactive Protein
CS / Corticosteroids
CTCAE / Common Terminology Criteria for Adverse Events
CV / Coefficient of Variation
DAS / Disease Activity Score
DMARD / Disease Modifying Anti-Rheumatic Drug
ESR / Erythrocyte Sedimentation Ratio
ETN / Etanercept
EU / European Union
EULAR / European League Against Rheumatism
FAS / Full Analysis Set
GCP / Good Clinical Practice
HAQ-DI / Health Assessment Questionnaire – Disability Index
ITT / Intention-to-Treat
JSN / Joint Space Narrowing
LEF / Leflunomide
mTSS / modified Total Sharp Score
MTX / Methotrexate
Nab / Neutralising Antibodies
NSAID / Non-Steroidal Anti-Inflammatory Drug
NRI / Non-Responder Imputation
PD / Pharmacodynamic
PK / Pharmacokinetic
PPS / Per Protocol Set
PsA / Psoriatic Arthritis
PSOR / Plaque Psoriasis
RA / Rheumatoid Arthritis
RF / Rheumatoid Factor
SAE / Serious Adverse Event
SD / Standard Deviation
SOC / System Organ Class
SSZ / Sulfasalazine
TB / Tuberculosis
TEAE / Treatment Emergent Adverse Event
Tmax / Time to Cmax
TNF / Tumour Necrosis Factor
TNFR / Tumour Necrosis Factor Receptor
ULN / Upper Limit of Normal
US / United States (of America)
VAS / Visual Analogue Scale
I.Introduction to product submission
Submission details
Type of submission: / New biological entityDecision: / Approved
Date of decision: / 15 July 2016
Date of entry onto ARTG / 22 July 2017
Active ingredient: / Etanercept (rch)
Product name: / Brenzys
Sponsor’s name and address: / Samsung Bioepis AU Pty Ltd,
201 Elizabeth Street, Sydney NSW 2000[2]
Dose form: / Solution for Injection
Strengths: / 50 mg and 50 mg
Containers: / Prefilled syringe
Auto-injector
Pack size: / 4s
Approved therapeutic use: / Adults(~ 18 years)
Rheumatoid arthritis
Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Brenzys can be used in combination with methotrexate.
Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.
Psoriatic arthritis
The signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate. Etanercept has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Plaque psoriasis
Adult patients with moderate to severe chronic Plaque psoriasis, who are candidates/phototherapy or systemic therapy
Ankylosing spondylitis
Non-radiographic AxialSpondyloarthritis
Treatmentofadultswithactive*non-radiographicaxial spondyloarthritiswithobjectivesigns ofinflammationasindicatedbyelevatedC-reactiveprotein(CRP)and/orMRIchangewhohave hadaninadequateresponsetoNSA/Ds.
*Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAIJ score of ≥4
Route(s) of administration: / Subcutaneous (SC)
Dosage: / 50 mg once weekly[3] see PI (Attachment 1) for further details.
ARTG numbers: / 245252 prefilled syringe and 245253 auto injector
Product background
This AusPAR describes the application by the sponsor, ERA Consulting (Australia) Pty Ltd,to register etanercept (Brenzys) as a biosimilar of the reference product etanercept (Enbrel) by Pfizer Australia Pty Ltd.
The sponsor is applying for the same indications as approved for Enbrel but only the adult indications and not the paediatric indications of juvenile idiopathic arthritis or paediatric plaque psoriasis as follows:
Brenzys is indicated for the treatment of:
Adults (≥ 18 years)
Rheumatoid arthritis
Active, adult rheumatoid arthritis (RA) in patients who have had inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs). Brenzys can be used in combination with methotrexate.
Severe, active rheumatoid arthritis in adults to slow progression of disease-associated structural damage in patients at high risk of erosive disease.
Psoriatic arthritis
The signs and symptoms of active and progressive psoriatic arthritis in adults, when the response to previous disease-modifying antirheumatic therapy has been inadequate.Etanercept has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Plaque psoriasis
Adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
Ankylosing spondylitis
The signs and symptoms of active ankylosing spondylitis in adults.
Non-radiographic Axial spondyloarthritis
Treatment of adults with active* non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change who have had an inadequate response to NSAIDs.
*Active disease is defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥ 4
Brenzys, also known as SB4,is not indicated for use in children less than 18 years of age. Brenzys is only presented as a 50 mg pre-filled syringe and 50 mg pre-filled auto-injector, while the recommended dose of etanercept for paediatric patients is 0.8 mg/kg given once weekly.
This is the first biosimilarversion of etanercept (Enbrel).
Etanercept is a soluble Tumour Necrosis Factor (TNF) receptor (TNFR) p75 fragment, crystallisable fusion protein that competitively inhibits human tumour necrosis (TNF) by binding to it, and thereby preventing the interaction between TNF and TNFR. As a consequence, TNF is rendered biologically inactive because TNF mediated signal transduction requires cell surfaces receptors to be cross-linked. Brenzys consists of a genetically produced dimer of a chimeric protein engineered by fusing the extracellular ligand binding domain of human TNFR-2 to the fragment crystallisable region domain of human IgG1. Brenzys is produced by DNA technology in a Chinese hamster ovary mammalian expression system.
In this submission, similarity to Enbrel (reference product) is claimed and the submission is clinically supported by a single pivotal Phase III study comparing the efficacy and safety of Brenzys with Enbrel in RA patients (with an open label extension) and a single Phase I study providing pharmacokinetic and safety data in healthy male volunteers.The development program for Brenzys was guided by the European Medicines Agency (EMA)and FDA requirements for biosimilar medicines.
The reference drug, Enbrel, used in the pivotal Phase III study was sourced from the European Union (EU) and a bridging comparability exercise was undertaken with the Australian registered Enbrel.The healthy volunteer study compared Brenzys with EU and US sourced Enbrel.
The TGA has produced a specific guideline in relation to biosimilar medicines, along with the adoption of numerous EU guidelinesthat explain the background to biosimilars and regulatory aspects.The TGA published guideline is called ‘Evaluation of biosimilars’ which was published on 30 July 2013 ( and was recently updated in December 2015.This guideline notes that a biosimilar medicine is a version of an already registered biological medicine that:
- Has a demonstrable similarity in physicochemical, biological and immunological characteristics, efficacy and safety, based on comprehensive comparability studies.
- Before a biosimilar medicine can be registered in Australia, a number of laboratory and clinical studies need to be performed to demonstrate the comparability (biosimilarity) of the new biosimilar to the reference biological medicine already registered in Australia.
- The TGA has adopted a number of European guidelines that outline the quality, nonclinical and clinical data requirements specific to biosimilar medicines; and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline on the assessment of comparability.
- For a biosimilar to be registered in Australia, the reference medicine must be a biological medicine that has been registered in Australia based on full quality, safety and efficacy data and the Australian reference medicine must have been marketed in Australia for a substantial period and have a volume of marketed use so that there is likely to be a substantial body of acceptable data regarding the safety and efficacy for the approved indications.However it may be possible for the sponsor to compare the biosimilar in certain clinical studies and in in vivonon-clinical studies to a medicine not registered in Australia in which case the reference medicine must be approved for general marketing by a regulatory authority with similar scientific and regulatory standards as the TGA (such as EMA or US FDA) and a bridging study must be provided to demonstrate that the comparability studies are relevant to the Australian reference medicine.
- To justify extrapolated indications based on the adopted EU guideline[4].
- To have a clearly distinguishable tradename from all other products and the active ingredient is to use the same name as the reference’s active ingredient without a specific biosimilar identifier suffix.The WHO is considering a naming convention for the active ingredients of all biological medicines, includingbiosimilars.
- The inclusion of comparative clinical trial information in the PI along with a clear distinction of the clinical trial information generated on the reference medicine.
- There may be post-registration requirements and all biosimilars must have an RMP.
There are a number of specific EU guidelines adopted by the TGA relevant to this submission, besides the general guidelines:
- CPMP/EWP/556/95 Rev 1: Points to Consider on Clinical Investigation of Medicinal Products other than NSAIDS for Treatment of Rheumatoid Arthritis. Replaces: CPMP/EWP/556/95 (Adopted by TGA February 2001). Effective: 29 January 2007
- EMEA/CHMP/EWP/438/04: Guideline on Clinical Investigation of Medicinal Products for the Treatment of Psoriatic Arthritis. Effective: 5 February 2008
- CPMP/EWP/4891/03: Guideline on Clinical Investigation of Medicinal Products for the Treatment of Ankylosing Spondylitis. Effective: 23 February 2010
- CHMP/EWP/2454/02: Guideline on clinical investigation of medicinal products indicated for the treatment of Psoriasis. Effective: 28 July 2005
- CHMP/437/04/Rev 1: Guideline on Similar Biological Medicinal Products. Effective: 25 May 2015
- EMEA/CHMP/BMWP/14327/2006: Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. Effective: 22 June 2009
- EMEA/CHMP/BMWP/42832/2005/Rev 1: Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substances: Non-Clinical and Clinical Issues. Effective: 1 July 2015
Regulatory status
This is an application for a new biological entity.
Brenzys has been approved in Europe (January 2016) under the name Benepali with only a 50 mg strength. It was also approved in Canada in August 2016. In Europe all five indications were approved however in Canada the sponsor has only applied for two indications of RA and Ankylosing Spondylitis (AS). The approved indications in Europe are as follows:
Rheumatoid arthritis
Benepali in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.
Benepali can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.
Benepali is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
Benepali, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.
Psoriatic arthritis
Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease modifying antirheumatic drug therapy has been inadequate. Etanercept has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.
Axial spondyloarthritis
Ankylosing spondylitis
Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.
Non-radiographic axial spondyloarthritis
Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).
Plaque psoriasis
Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (see section 5.1).
Product Information
The Product Information (PI) approved with the submission which is described in this AusPAR can be found as Attachment 1. For the most recent PI, please refer to the TGA website at
II. Qualityfindings
Drug substance (active ingredient)and Drug product
Structure
Brenzysis a homodimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human TNFR2/p75 to the Fc domain of human IgG1. SB4 is produced by Chinese hamster ovary (CHO) cell expression system as a dimeric, secreted, soluble protein.The Fc component comprises the hinge, CH2 and CH3 regions but the CH1 region is excluded.The Fc region is dimerised via 3 disulphide bonds. SB4 consists of 934 amino acids (467 for the single chain) and has a molecular weight (MW) of approximately 130 kDa.Below is a schematic structure of Brenzys.
Figure 1: Schematic structure
MW: 130 kD
The drug product contains etanercept (ETN), sucrose, sodium chloride, Sodium phosphate monobasic monohydrate, Sodium phosphate dibasic heptahydrate and Water for Injection.
Biosimilarity
Enbrel etanercept (rch) 50mg solution for injection pre-filled syringe (AUST R 124422) is the reference product in the studies.The studies used a non-Australian reference product (EU Enbrel); as the EU Enbrel is manufactured from a different site as the Australian registered product (AU Enbrel), the company also provided a bridging comparability study between AU Enbrel and EU Enbrel.
Analytical test methods were selected from the methods applied in the similarity assessment based on ICH Q6B[5].Each category except[information redacted]included at least one representative method to demonstrate the comparability.
The structural, physicochemical and biophysical attributes of SB4 and EU Enbrel (AU Enbrel) were studied.Based on all the comparison studies, biosimilarity has been fully demonstrated with respect to quality aspects between SB4 and Enbrel.